Medicare New Technology Add-On Payment Awards For Hospital Drugs On The Rise
Executive Summary
Eight inpatient prescription drugs are deemed eligible for supplemental payments in 2020, a big increase from years past, based on a review of US Medicare's new technology add-on payment approvals for prescription drugs since 2011.
You may also be interested in...
Antibiotics: Leveraging Off-Label Efficacy Data Needed To Drive Appropriate Use, Reimbursement
Clinicians and sponsors want the US FDA to open up antibacterial labeling to include more data on efficacy against resistant pathogens and in other body sites, but regulatory restrictions may require a workaround in the form of rapid, peer-to-peer communications about the data on new products.
New Tech Payment For Old Antibiotics: US Medicare Effort Brings Lots Of Interest
CMS streamlined process for enhanced payments is having an impact: seven antibiotic applications for New Technology Add-On Payment status in 2021—including one for a product that has been marketed for more than five years.
Progress Being Made With Cell And Gene Therapy Market Access, But Challenges Remain
Drug developers and payers are coming together long before product approvals to work out payment options for high-cost, high-impact cell and gene therapies, but challenges like portability of commercially insured patients and Medicaid best price requirements remain.